1.
Int J Dermatol
; 47(9): 957-9, 2008 Sep.
Artículo
en Inglés
| MEDLINE
| ID: mdl-18937663
RESUMEN
Pegylated interferon-alpha in combination with ribavirin currently represents the therapeutic standard for the hepatitis C virus infection. Interferon based therapy may be responsible for many cutaneous side effects. We report a case of drug-induced Sweet's syndrome secondary to hepatitis C antiviral therapy. To our knowledge, this is the first reported case of Sweet's syndrome in association with pegylated interferon-alpha therapy.